Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT01369511
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01367262
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of LY2881835 in Healthy People and People With Diabetes
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01358981
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01358968
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States
A Study of LY2409021 Formulations and the Effect of Food
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2409021 Test-Med Formulation (medium particle size)Drug: LY2409021 Reference FormDrug: LY2409021 Test-High Formulation (high particle size)Drug: LY2409021 Test-Low Formulation (low particle size)
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT01354496
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your person physician., Singapore, Singapore
A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 383
- Registration Number
- NCT01352507
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-05-03
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT01346358
- Locations
- 🇺🇸
The Angeles Clinic & Research Institute, Los Angeles, California, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 17
- Registration Number
- NCT01341457
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan
A Phase 1 Study of LY2787106 in Cancer and Anemia
- Conditions
- Anemia
- Interventions
- Dietary Supplement: Iron Supplementation
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT01340976
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States
A Study of LY2495655 in Healthy Subjects
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01341470
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States